ArticleExperimental & molecular medicine2026
Engineered macrophages with IL-10-TLR9 signal switch receptors for reprogramming tumor microenvironment and enhancing antitumor immunity.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T cell immunotherapy has achieved remarkable success in hematologic malignancies, prompting the exploration of CAR strategies in solid tumors. Here, we developed a CAR-like signal-switching receptor-macrophage (SR CAR-M) that recognizes IL-10, a major immunosuppressive cytokine enriched in solid tumors, and converts this inhibitory signal into a pro-inflammatory activation through the Toll-like receptor 9 (TLR9) intracellular signaling pathway. SR CAR-Ms effectively blocked IL-10-mediated STAT3 phosphorylation while activating TLR9 downstream signaling, including nuclear translocation of nuclear factor-κB and upregulation of IRF1, thereby adopting an M1-like phenotype with enhanced phagocytic capacity and tumor cytotoxicity. Domain-deletion controls demonstrated that both IL-10 binding and TLR9 signaling are indispensable. In addition, SR CAR-Ms promoted dendritic cell maturation, enhanced T cell proliferation and effector function, and prevented T cell exhaustion. In an orthotopic 4T1 breast cancer model, infused SR CAR-Ms selectively accumulated in tumors, depleted local IL-10 while inducing inflammatory cytokine production, suppressed tumor growth, and prolonged survival without systemic toxicity. The signal-switching mechanism was validated in primary bone marrow-derived macrophages and human monocyte-derived macrophages, supporting the translational applicability. Further enhancement was achieved by engineering dual-function SRPα CAR-Ms secreting anti-PD-L1 antibodies, which outperformed either SR CAR-M or anti-PD-L1 monotherapy. The SR CAR-M platform transforms an immunosuppressive cytokine into a location-specific activation trigger, simultaneously depleting the inhibitory signal and remodeling the tumor microenvironment. This signal-switching paradigm offers a versatile approach for treating solid malignancies that are resistant to conventional immunotherapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.